Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017

Datos Bibliográficos

ID9100764
AutoresHaiden A Huskamp (0000-0002-1860-3956, Harvard Medical School, autor de correspondencia), Lauren E Riedel (Harvard Medical School), Lauren Riedel (Harvard University, autor de correspondencia), Colleen L Barry (0000-0001-8211-5036, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD), Alisa B Busch (0000-0002-1828-9098, McLean Hospital, Belmont, MA)
Año2018
Volumen56
Número6
Páginas505-509
Fecha de publicación2018-06-01
Peer ReviewedSí
Open AccessNo
TipoARTICLE
RevistaMedical Care (JOURNAL)
Identificadores de la revistaISSN: 0025-7079 • E-ISSN: 1537-1948
EditorialOvid Technologies (Wolters Kluwer Health) (PUBLISHER)
DOI10.1097/mlr.0000000000000918
PMID29668645
OpenAlexW2800476884
IdiomaEN
Citas recibidas6
Referencias citadas14

BACKGROUND: Efficacious medications to treat opioid use disorders (OUDs) have been slow to diffuse into practice, and insurance coverage limits may be one important barrier. OBJECTIVES: To compare coverage for medications used to treat OUDs and opioids commonly prescribed for pain management in plans offered on the 2017 Health Insurance Marketplace exchanges. RESEARCH DESIGN: We identified a sample of 100 plans offered in urban and in rural counties on the 2017 Marketplaces, weighting by population. We accessed publicly available plan coverage information on healthcare.gov for states with a federally facilitated exchange, the state exchange website for state-based exchanges, and insurer websites. RESULTS: About 14% of plans do not cover any formulations of buprenorphine/naloxone. Plans were more likely to require prior authorization for any of the covered office-based buprenorphine or naltrexone formulations preferred for maintenance OUD treatment (ie, buprenorphine/naloxone, buprenorphine implants, injectable long-acting naltrexone) than of short-acting opioid pain medications (63.6% vs. 19.4%; P<0.0001). Only 10.6% of plans cover implantable buprenorphine, 26.1% cover injectable naltrexone, and 73.4% cover at least 1 abuse-deterrent opioid pain medication. CONCLUSIONS: Many Marketplace plans either do not cover or require prior authorization for coverage of OUD medications, and these restrictions are often more common for OUD medications than for short-acting opioid pain medications. Regulators tasked with enforcement of the Mental Health Parity and Addiction Equity Act, which requires that standards for formulary design for mental health and substance use disorder drugs be comparable to those for other medications, should focus attention on formulary coverage of OUD medications

(+)-Naloxone · Addiction · Buprenorphine · Environmental health · Health care · Hydromorphone · Naltrexone · Opioid · Opioid use disorder · Population · Prior authorization · Psychiatry · HIV, Drug Use, Sexual Risk · Medicine · Opioid Use Disorder Treatment · Pharmacology · Substance Abuse Treatment and Outcomes